Baker Hughes initiated with a Neutral at UBS

UBS analyst Josh Silverstein initiated coverage of Baker Hughes with a Neutral rating and $31 price target. The corporate restructuring supports Baker Hughes reaching 20% segment level EBITDA margins by year-end 2025, and while positive, this is already reflected in estimates, limiting EPS and share price upside, the analyst tells investors in a research note.